Related Experiment Video
Updated: Jul 9, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Exploiting signal transduction pathways in acute myelogenous leukemia
Alexander E Perl1, Martin Carroll
1Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, USA. Alexander.Perl@uphs.upenn.edu
Current Treatment Options in Oncology
|December 22, 2007
Summary
Signal transduction inhibitors show promise for treating acute myeloid leukemia (AML), with tipifarnib demonstrating clinical benefit. Combining these inhibitors with chemotherapy may improve response rates in AML treatment.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Acute myeloid leukemia (AML) treatment relies on cytotoxic chemotherapy, offering temporary control but limited cures.
- Signal transduction inhibitors represent a promising therapeutic avenue for AML, though monotherapy benefits over traditional chemotherapy are not yet established.
- Tipifarnib is a notable exception, showing reproducible clinical benefit in AML when assessed by standard chemotherapy response criteria.
Purpose of the Study:
- To evaluate the potential of signal transduction inhibitors in AML therapy.
- To explore the efficacy of tipifarnib as a monotherapy and in combination treatments.
- To discuss the ongoing research and challenges in optimizing AML treatment strategies using targeted therapies.
Main Methods:
- Review of existing clinical data and response criteria for AML treatments.
- Analysis of signal transduction inhibitors, including tipifarnib, FLT3 inhibitors, and others targeting pathways like ras/raf/MAPK, mTOR, KIT, and VEGF.
- Examination of ongoing clinical trials investigating combination therapies and novel drug development.
Main Results:
- Tipifarnib demonstrates clinical benefit in AML, though its advantages over chemotherapy require Phase III confirmation due to toxicity and response rates.
- Combining signal transduction inhibitors with chemotherapy is hypothesized to improve response rates.
- Clinical trials are actively investigating various targeted agents and combinations, but optimal approaches remain undefined.
Conclusions:
- Signal transduction inhibitors hold significant potential for advancing AML therapy, particularly in combination regimens.
- Further research, including Phase III studies, is crucial to confirm the benefits of agents like tipifarnib and to define optimal treatment strategies.
- Understanding the precise mechanisms of action and identifying predictive biomarkers are essential for effective clinical trial design and drug development in AML.
Related Concept Videos
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Signal Transduction: Overview
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...